THOMAS MARX AND BORIS GREBER DISCUSS THE POTENTIAL OF IPSCs
In an informative interview with Michael Adeniya, Portfolio Director of Phacilitate Exchange, Boris Greber and Thomas Marx answer questions about the position of induced pluripotent stem cells in today’s advanced therapies market and the transformative power latent in their clinical application.
In a 30-minute conversation, the three gentlemen talk about the beginnings of RheinCell Therapeutics and explore a rise in demand for iPSCs to underscore the development of cell therapies. They detail work that was necessary to get iPSCs to the point where they can be used as a plug-in starting material – from method development to GMP certification and creating a robust manufacturing and banking process. They close the interview with a view on the future of the company.
Read the interview here